A new player in the development of TRAIL based therapies for hepatocarcinoma treatment: ATM kinase

Venturina Stagni, Simonetta Santini, Daniela Barilà

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. HCCs are genetically and phenotypically heterogeneous tumors characterized by very poor prognosis, mainly due to the lack, at present, of effective therapeutic options, as these tumors are rarely suitable for radiotherapy and often resistant to chemotherapy protocols. In the last years, agonists targeting the Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) death receptor, has been investigated as a valuable promise for cancer therapy, based on their selectivity for malignant cells and low toxicity for healthy cells. However, many cancer models display resistance to death receptor induced apoptosis, pointing to the requirement for the development of combined therapeutic approaches aimed to selectively sensitize cancer cells to TRAIL. Recently, we identified ATM kinase as a novel modulator of the ability of chemotherapeutic agents to enhance TRAIL sensitivity. Here, we review the biological determinants of HCC responsiveness to TRAIL and provide an exhaustive and updated analysis of the molecular mechanisms exploited for combined therapy in this context. The role of ATM kinase as potential novel predictive biomarker for combined therapeutic approaches based on TRAIL and chemotherapeutic drugs will be closely discussed.

Original languageEnglish
Pages (from-to)354-378
Number of pages25
JournalCancers
Volume4
Issue number2
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Phosphotransferases
Tumor Necrosis Factor-alpha
Apoptosis
Ligands
Neoplasms
Death Domain Receptors
Hepatocellular Carcinoma
Therapeutics
Radiotherapy
Biomarkers
Drug Therapy
Pharmaceutical Preparations

Keywords

  • ATM kinase
  • Combined therapy
  • Hepatocellular carcinoma
  • TRAIL

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A new player in the development of TRAIL based therapies for hepatocarcinoma treatment : ATM kinase. / Stagni, Venturina; Santini, Simonetta; Barilà, Daniela.

In: Cancers, Vol. 4, No. 2, 06.2012, p. 354-378.

Research output: Contribution to journalArticle

@article{9c771d4f156d43a8aa97870906a8aef7,
title = "A new player in the development of TRAIL based therapies for hepatocarcinoma treatment: ATM kinase",
abstract = "Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. HCCs are genetically and phenotypically heterogeneous tumors characterized by very poor prognosis, mainly due to the lack, at present, of effective therapeutic options, as these tumors are rarely suitable for radiotherapy and often resistant to chemotherapy protocols. In the last years, agonists targeting the Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) death receptor, has been investigated as a valuable promise for cancer therapy, based on their selectivity for malignant cells and low toxicity for healthy cells. However, many cancer models display resistance to death receptor induced apoptosis, pointing to the requirement for the development of combined therapeutic approaches aimed to selectively sensitize cancer cells to TRAIL. Recently, we identified ATM kinase as a novel modulator of the ability of chemotherapeutic agents to enhance TRAIL sensitivity. Here, we review the biological determinants of HCC responsiveness to TRAIL and provide an exhaustive and updated analysis of the molecular mechanisms exploited for combined therapy in this context. The role of ATM kinase as potential novel predictive biomarker for combined therapeutic approaches based on TRAIL and chemotherapeutic drugs will be closely discussed.",
keywords = "ATM kinase, Combined therapy, Hepatocellular carcinoma, TRAIL",
author = "Venturina Stagni and Simonetta Santini and Daniela Baril{\`a}",
year = "2012",
month = "6",
doi = "10.3390/cancers4020354",
language = "English",
volume = "4",
pages = "354--378",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "2",

}

TY - JOUR

T1 - A new player in the development of TRAIL based therapies for hepatocarcinoma treatment

T2 - ATM kinase

AU - Stagni, Venturina

AU - Santini, Simonetta

AU - Barilà, Daniela

PY - 2012/6

Y1 - 2012/6

N2 - Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. HCCs are genetically and phenotypically heterogeneous tumors characterized by very poor prognosis, mainly due to the lack, at present, of effective therapeutic options, as these tumors are rarely suitable for radiotherapy and often resistant to chemotherapy protocols. In the last years, agonists targeting the Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) death receptor, has been investigated as a valuable promise for cancer therapy, based on their selectivity for malignant cells and low toxicity for healthy cells. However, many cancer models display resistance to death receptor induced apoptosis, pointing to the requirement for the development of combined therapeutic approaches aimed to selectively sensitize cancer cells to TRAIL. Recently, we identified ATM kinase as a novel modulator of the ability of chemotherapeutic agents to enhance TRAIL sensitivity. Here, we review the biological determinants of HCC responsiveness to TRAIL and provide an exhaustive and updated analysis of the molecular mechanisms exploited for combined therapy in this context. The role of ATM kinase as potential novel predictive biomarker for combined therapeutic approaches based on TRAIL and chemotherapeutic drugs will be closely discussed.

AB - Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. HCCs are genetically and phenotypically heterogeneous tumors characterized by very poor prognosis, mainly due to the lack, at present, of effective therapeutic options, as these tumors are rarely suitable for radiotherapy and often resistant to chemotherapy protocols. In the last years, agonists targeting the Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) death receptor, has been investigated as a valuable promise for cancer therapy, based on their selectivity for malignant cells and low toxicity for healthy cells. However, many cancer models display resistance to death receptor induced apoptosis, pointing to the requirement for the development of combined therapeutic approaches aimed to selectively sensitize cancer cells to TRAIL. Recently, we identified ATM kinase as a novel modulator of the ability of chemotherapeutic agents to enhance TRAIL sensitivity. Here, we review the biological determinants of HCC responsiveness to TRAIL and provide an exhaustive and updated analysis of the molecular mechanisms exploited for combined therapy in this context. The role of ATM kinase as potential novel predictive biomarker for combined therapeutic approaches based on TRAIL and chemotherapeutic drugs will be closely discussed.

KW - ATM kinase

KW - Combined therapy

KW - Hepatocellular carcinoma

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=84862648880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862648880&partnerID=8YFLogxK

U2 - 10.3390/cancers4020354

DO - 10.3390/cancers4020354

M3 - Article

C2 - 24213315

AN - SCOPUS:84862648880

VL - 4

SP - 354

EP - 378

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 2

ER -